Europe Radiotherapy Market
Radiotherapy is a painless treatment which is extensively used in cancer treatment. It works on a principle of damaging cancerous cells by destruction of DNA inside cells by radiation. It slows down the cancerous cells growth and provides comfort by relieving the patients with cancer symptoms. Cancer is the abnormal growth and spread of cells which arises from a change in single cell. Change may be due to external agents and inherited genetic factors and can affect almost any body part. Cancer can be prevented by avoiding exposure to the common risk factors, by surgery, radiotherapy and chemotherapy.
Radiotherapy market in Europe is driven by various factors like growing number of cancer patients, favourable non-government and government funds in R&D of cancer treatment. Furthermore, inclination towards non-invasive techniques and decreased cost of treatment in the developed areas are expected to boost the growth of the radiotherapy market in Europe. However, side effects like skin problems, fertility issues, loss of hair and appetite and also harms caused to other healthy cells because of high dosage of radiation will restrain the growth of radiotherapy market in Europe. Moreover, costs associated with training the professionals, difficulty in maintenance and up gradation of equipment are expected to hamper the Europe radiotherapy market.
The Europe radiotherapy market is classified on the basis of type, application, equipment, end user, and geography.
Based on equipment, the Europe radiotherapy market is segmented into the following
- Radiation therapy stimulators
- Treatment planning systems
- Linear Accelerators
Based on type, the Europe radiotherapy market is segmented into the following
- External therapy
- Intensity modulated therapy
- External beam therapy
- Image-guided radiation therapy
- Stereotactic body radiation therapy
- Intraoperative radiation therapy
- Electron therapy
- Proton Therapy
- Internal therapy
- Radioisotope or radionuclide therapy
Based on application, the Europe radiotherapy market is segmented into the following
- Skin and lip cancer
- Head and neck cancer
- Breast cancer
- Prostate cancer
- Cervical cancer
- Lung cancer
- Spine cancer
Based on end user, the Europe radiotherapy market is segmented into the following
- Oncology centers
- R&D centers
- Diagnostic centers
Europe has wide variances in accessing radiation therapy services, scantiness in infrastructure and skilled professionals. As per, International Atomic Energy Agency (IAEA) report 2012, about 1286 radiotherapy centres registered in DIRAC database in Europe. Where Germany has the largest number with 289 centres, France with 177, Italy with 172 centres and Spain has 117 centres respectively. Netherlands and UK along with Nordic countries (Scandinavia, Finland and Iceland) have the most centralized radiotherapy infrastructure with more treatment equipment and fewer facilities at each centre.
The European market is expanding with both new and old technologies. Most prevalent cancers in the European region are breast cancer, prostate cancer, colorectal and lung cancer. Europe radiotherapy market is segmented into major countries like UK, Germany, France, Spain, Switzerland, Netherlands, Italy, Russia and rest of the Europe. In recent year, there has been a rapid development in the radiotherapy field in Europe region owing to growing threat of multiple cancers and mortality rate which has pulled the government and healthcare manufacturers in increasing funds for research labs to develop treatments and preventive techniques to treat cancer.
Some of the players in Europe radiotherapy market are Ion Beam Applications SA (Belgium), RaySearch Laboratories AB (Sweden), Elekta AB (Sweden), Nordion Inc. (Canada), C. R. Bard Inc. (U.S.), Varian Medical Systems Inc. (U.S.), Mevion Medical Systems Inc. (U.S.), IsoRay Medical Inc. (U.S.), Mitsubishi Electric Corporation (Japan) and Accuray Incorporated (U.S.).
- In February 2017, Elekta and European Society for Radiotherapy and Oncology (ESTRO) Cancer Foundation (ESF) to contribute the mission of “every patient in Europe will have access to state of the art of radiation.
- In June 2011, Cayman chemical company has adopted Genedata screener of Genedata, the company of advanced software solutions for drug discovery and life science research as a data management platform for cayman’s new epigenetic screening laboratory.
- The report provides granular level information about the market size, regional market share, and forecast from 2017-2023
- The report covers in-detail insights about the competitor’s overview, key findings, and their key strategies
- The report outlines drivers, restraints, challenges, and trends that are currently faced by the industry
- The report tracks recent innovations, key developments, and startup’s details that are working in the industry
- The report provides plethora of information about market entry strategies, regulatory framework, and reimbursement scenario